AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platf ...

Core Viewpoint - Red Light Holland Corp. has engaged Kala Bio's Researgency.ai platform to enhance the clinical development strategy for its psilocybin drug candidate PEX010, aiming to leverage AI for improved research capabilities and accelerated drug development timelines [1][3][7]. Group 1: Company Developments - Red Light has entered a definitive arrangement agreement to acquire Filament Health Corp., which includes a portfolio of 76 issued patents across 15 patent families, significantly enhancing its intellectual property in botanical psilocybin drug development [2]. - PEX010 is currently supplied to over 70 clinical research sites globally and is being studied for various mental health conditions, including alcohol use disorder and treatment-resistant depression [4][8]. - The drug candidate has received authorization for clinical trials from both Health Canada and the U.S. Food and Drug Administration, demonstrating positive Phase 2 clinical data in alcohol use disorder [5]. Group 2: Strategic Rationale - The integration of the Researgency.ai platform is a strategic move for Red Light to enhance its psychedelic drug development capabilities, focusing on research planning, scenario simulation, and protocol optimization [3][6]. - The Researgency.ai platform is designed to create autonomous research loops that can generate and optimize study scenarios, compressing timelines and expanding viable options for clinical trials [6][11]. Group 3: Management Commentary - Management emphasizes that utilizing Kala Bio's AI platform is a natural progression in building a leading psychedelic drug development operation, aiming to strengthen study designs and accelerate decision-making processes [7]. - The CEO of Filament Health highlights the importance of advanced analytical tools in evaluating clinical development strategies as the program evolves [7]. - Kala Bio's CEO notes that the deployment of Researgency.ai addresses high-value, data-intensive challenges in psychedelic drug development, which can significantly impact clinical scenario evaluations [7].

Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulationCombines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidateAll-share transaction in which existing Red Light shareholders are ex ...

As filed with the Securities and Exchange Commission on October 14, 2025 Registration No. 333-289285 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to Form F-3 on Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Psyence Biomedical Ltd. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Ontario, Canada 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (I.R.S. ...

As filed with the Securities and Exchange Commission on October 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form F-3 on Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Psyence Biomedical Ltd. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Ontario, Canada 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Numbe ...

Table of Contents As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. 333-276973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Primary Standard Industrial Classification Code Number) 121 Richmond Street West Penthouse Suite 1300 (I.R.S. Employer Identification Number) Toronto, Ontario MK5 2K1 Telephone: + 1 (416) 346-7764 (Address, including zip code, and telephone ...

Table of Contents As filed with the Securities and Exchange Commission on May 6, 2024 Registration No. 333-276973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Psyence Biomedical Ltd. (Exact Name of Registrant as Specified in Its Charter) Ontario, Canada 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) 121 Ric ...

Table of Contents As filed with the Securities and Exchange Commission on April 17, 2024 Registration No. 333-276973 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Psyence Biomedical Ltd. (Exact Name of Registrant as Specified in Its Charter) Ontario, Canada 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) 121 ...

Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Psyence Biomedical Ltd. (Exact Name of Registrant as Specified in Its Charter) As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. 333- (State or Other Jurisdiction of Incorporation or Organization) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 21 Richmond Street West Penthouse Suite 1 ...